AstraZeneca says advanced trial of breast-cancer drug Capivasertib meets primary endpoints
admin AstraZeneca PLC said Wednesday that Capivasertib plus Faslodex significantly improved progression-free survival when compared with…
Read MoreAstraZeneca PLC said Wednesday that Capivasertib plus Faslodex significantly improved progression-free survival when compared with…
Read More